This is the first publication to provide an in-depth description of the anti-cancer activity of capsaicin sustained-release formulations. The research team was led by Associate Professor of Biomedical Sciences Piyali Dasgupta, Ph.D., and Professor of Biomedical Sciences Monica Valentovic, Ph.D....CONTINUE READING THE FULL ARTICLE>>>
This review article is the first to provide a comprehensive overview of capsaicin formulations in human cancer,” said Dasgupta, corresponding author of the publication. ” Previous publications in the literature only briefly address sustained-release formulations of capsaicin.”
The nutritional agent capsaicin displayed robust growth-inhibitory activity in a diverse array of human cancers. However, the clinical applications of capsaicin as a viable anti-cancer agent were hindered by three factorspoor solubility, low bioavailability, and spicy flavor.
Oral use of capsaicin is associated with unfavorable side effects such as stomach cramps, nausea, a burning sensation in the gut, and gastrointestinal irritation,” said Valentovic, a senior author on the publication.
A strategy to overcome these drawbacks is the development of different delivery systems, such as encapsulating capsaicin in long-acting sustained release drug delivery systems could allow for more consistent capsaicin levels that could be more efficient as anti-cancer agents.”
